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Abstract 
 
The genetic factors determining the progression of prodromal syndromes 
to first episode schizophrenia have remained enigmatic to date. In a 
unique prospective multicentre trial we assessed whether variants at the 
D-amino acid oxidase activator (DAOA)/G72 locus influence progression 
to psychosis. Young subjects with a prodromal syndrome were observed 
prospectively for up to 2 years to assess the incidence of progression to 
schizophrenia or first episode psychosis. Of 82 probands with a 
prodromal syndrome, 21 probands experienced progression to psychosis 
within the observation period. Assessment of nine common variants in 
the DAOA/G72 locus yielded two variants with predictive value for 
symptom progression: all four probands with the rs1341402 CC 
genotype developed psychosis, compared to 17 out of 78 probands with 
the TT or CT genotypes (chi2 =12.348; df =2; p= 0.002). The relative risk 
for progression to psychosis was significantly increased in the CC 
genotype: RR=4.588 (95% C.I.=2.175-4.588). Similarly, for rs778294, 
50% of probands with the AA genotype, but only 22 % of probands with a 
GG or GA genotype progressed to psychosis (chi2 = 7.027; df= 2; p = 
0.030). Moreover, haplotype analysis revealed a susceptibility haplotype 
for progression to psychosis. This is one of the first studies to identify a 
specific genetic factor for the progression of prodromal syndromes to 
schizophrenia, and further underscores the importance of the DAOA/G72 
gene for schizophrenia. 
 
Keywords: schizophrenia, prodromal, progression, D-amino acid 
oxidase activator, G72 gene 
 
 Introduction 
 
The development of a first episode of schizophrenia is often preceded by 
prodromal states with variable symptoms [22]. The factors determining 
the progression of disease from a prodromal state to a psychotic episode 
are of great interest [3]. However, very little is currently known about the 
factors influencing whether a prodromal proband progresses to 
psychosis or remains stable [6]. We hypothesized that genetic variants 
play an important role in determining symptom progression. Among the 
schizophrenia susceptibility genes identified in the past few years [15], 
we focused on a well characterised schizophrenia susceptibility locus, 
DAOA/G72, and queried whether variants in this locus might influence 
this progression. 
 
The DAOA/G72 gene was originally discovered during the analysis of the 
schizophrenia susceptibility region on chromosome 13. Finemapping of 
the region on the long arm of chromosome 13, 13q12 – 13q34, led to the 
discovery of the new gene G72 [4]. Variants in this gene were related to 
schizophrenia in Canadian and Russian subjects. The G72 gene is 
transcribed in brain, and increased expression was found in the  
dorsolateral prefrontal cortex in schizophrenia, compared to controls [12]. 
To assess the function of this gene, a screen of binding proteins was 
performed, which showed that G72 binds to and activates D-amino acid 
oxidase. Therefore, G72 was named D-amino acid oxidase activator 
(DAOA) [4]. DAOA/G72 is a very attractive schizophrenia candidate gene 
also due to the fact that it is a primate – specific gene [4]. A recent meta-
analysis of DAOA/G72 in schizophrenia showed highly significant 
evidence of association between a number of markers in the DAOA/G72 
region and schizophrenia [5]. These authors concluded that the 
association findings for the DAOA/G72 gene and schizophrenia are 
amongst the most compelling in psychiatry. This led us to focus on the 
DAOA/G72 gene, since we expected a sufficiently large effect to be 
visible in a prospective investigation. 
 
The main outcome measure of the present study was progression to a 
psychosis, namely the incidences of first episode schizophrenia and first 
episode psychosis. In a unique prospective multicenter approach 
combining psychopathology and genetics, prodromal subjects were 
followed for up to two years to prospectively identify those probands who 
would progress to psychosis. Specifically, we assessed here whether 
common DAOA/G72 variants might predict the conversion to a psychosis 
in this prospective multicentre study. We analysed a number of variants 
which are located in the coding region of DAOA/G72, but also variants in 
the 5´ and 3´  putative regulatory regions which are expected to have an 
important role in the function and expression of the DAOA/G72 gene. 
 
Materials and Methods 
 
Study subjects 
The clinical study was conducted at three early detection and 
intervention centres. The centres were located at the Departments of 
Psychiatry and Psychotherapy at the Universities of Bonn, Cologne, and 
Düsseldorf. To aid in the recruitment of probands with prodromal 
syndromes, awareness programmes were put in place for primary and 
psychiatric health services, for the relatives of patients with 
schizophrenia, and were also aimed to inform youth support services as 
well as the general population. The aims of the programmes were to 
establish local mental health networks as well as the facilitation for 
persons at risk to find help with the early intervention services. 
Information was provided about early symptoms of schizophrenia as well 
as about the usefulness of early intervention. Referrals of probands were 
from a number of settings, including from counselling services, youth 
support services, primary health care, and mental health professionals 
[11].  
 
The clinical study and the inclusion and exclusion criteria are described 
in more detail elsewhere [1]. Briefly, patients were eligible for inclusion in 
the trial if they met the criteria of the early or late initial prodromal state 
and did not fulfil exclusion criteria. The early initial prodromal state was 
operationally defined by either basic symptoms predicting psychosis [10] 
or by a clinically relevant decline of functioning in combination with 
established risk factors (Risk and Decreased Functioning) [22].  Basic 
symptoms required the presence of one or more of the following 
symptoms several times per week during the last three months: thought 
interferences, thought perseverations, thought pressure, thought 
blockages, disturbances of receptive language, decreased ability to 
discriminate between ideas and perception or between fantasy and true 
memory contents, tendency to delusion of reference with subject-
centrism, derealisation, visual perception disturbances, and acoustic 
perception disturbances.  Established risk factors were pre- or perinatal 
complications or a first-degree relative with a lifetime diagnosis of 
schizophrenia or a schizophrenia spectrum disorder. Late initial 
prodromal state was defined by the presence of at least one of the 
following symptoms appearing several times a week: ideas of reference, 
odd beliefs or magical thinking, unusual perceptual experiences, odd 
thinking and speech, or suspiciousness or paranoid ideation; or by the 
appearance of one of the following symptoms for less than one week and 
resolving spontaneously: hallucinations, delusions, formal thought 
disorder, or gross disorganised or catatonic behavior. Probands were 
only included if aged between 17 and 42 years. Exclusion criteria of note 
were previous treatment with antipsychotics, present or past diagnosis of 
a schizophrenic, schizophreniform, schizoaffective, delusional, or bipolar 
disorder, present or past diagnosis of a brief psychotic disorder with a 
duration of more than one week or within the last four weeks regardless 
of its duration, organic brain disease, and alcohol or drug dependence 
within the last three months. During the study, probands were seen 
approximately once a month. Progression to first episode psychosis was 
operationally defined by cut-off points on Positive And Negative 
Syndrome Scale (PANSS) [8] subscales of 4 or more on hallucinations, 4 
or more on delusions and 5 or more on conceptional disorganisation or 
formal thought disorder for at least 7 days and meeting criteria for 
schizophrenia (ICD-10: F20) or acute schizophrenia-like psychotic 
disorder (ICD-10: F23.2). The study was approved by the appropriate 
ethics committees.  
 
Genotyping 
Nine common variants spanning the DAOA/G72 gene were identified 
from the UCSC genome browser (genome.cse.ucsc.edu). Single 
nucleotide polymorphism nomenclature is based on NCBI dbSNP build 
129 (April 2008, updated June 2008). Moreover, the traditional M 
nomenclature as described by Chumakov et al. is given, whenever 
applicable [4]. Venous blood was taken at study entry and DNA extracted 
by standard protocols. DAOA/G72 variants were genotyped by allele 
discrimination using TaqMan technology.  12.5 ng of DNA was used for 
TaqMan SNP genotyping assays on demand, employing the Applied 
Biosystems protocol.  After completion of PCR reactions, fluorescence 
was determined on a Tecan 384 Ultra reader (Tecan USA, Durham, NC).  
The probes were labelled with carboxyfluorescein (FAM), with an 
excitation wavelength of 485nm and an emission wavelength of 535 nm.  
VIC-labelled probes employed an excitation wavelength of 535 nm and 
an emission wavelength of 590 nm. 
 
Statistical analysis 
The influence of DAOA/G72 variants on progression of symptoms was 
assessed by chi2–tests, employing SPSS version 14.0 (SPSS, Chicago, 
USA). If cells had an expected frequency of less than 5, Monte Carlo 
simulation based on 10000 permutations with the start value 92208573 
was done. The level of significance was set at p<0.05 (two-sided). To 
correct for multiple testing, the spectral decomposition method was 
employed to estimate the number of effective loci [14, 17]. Age 
distribution of the proband groups was assessed by ANOVA. Haplotype 
block structure was determined by the solid spine of LD method as 
implemented in Haploview (Broad Institute, Mass, USA). Haplotype 
analysis was performed employing the program Famhap 17 [2]. Famhap 
17 yields a global significance value of the haplotype analysis employing 
the likelihood ratio test, as well as individual p-values for each haplotype. 
Individual haplotype p-values were subsequently corrected for multiple 
testing employing Bonferroni correction. 
 
 
  
Results 
 
Eighty-two probands were enrolled in the prospective study of early 
prodromal states. They were followed longitudinally and were assessed 
for progression to psychosis. DNA was obtained for subsequent 
determination of DAOA/G72 variants. The mean age of the probands 
was 26.3 ± 7.1 years. 21 probands experienced a progression of 
symptoms to schizophrenia or first episode psychosis. The mean 
duration for progression to psychosis was 29.7 weeks (range: 2 – 86 
weeks).The mean age of those patients progressing to psychosis was 
24.2 ± 5.0 years and they were thus on average slightly younger than 
those probands who remained stable (27.0 ± 7.6 years; F= 3.139; 
p=0.083 by Welch test). The gender distribution did not differ between 
the probands who progressed and those who remained stable (chi2= 
1.320; df=1; p=0.251).  
 
We then queried whether the likelihood of progression to psychosis is 
related to variants of the DAOA/G72 gene. Two variants were found to 
have an impact on the progression to psychosis. Thus, for rs1341402, 
20.4 % of probands with the TT Genotype and 24.1 % of heterozygous 
probands (TC genotype) progressed to psychosis (table 1). In contrast, 
all homozygous CC probands progressed to psychosis. This effect was 
statistically significant (chi2= 12.348, df=2, p=0.002). This finding 
remained significant after correction for multiple testing with the spectral 
decomposition method [14, 17]: with an effective number of independent 
marker loci of 5, the significance threshold is p=0.01. A weaker effect 
was seen for another DAOA/G72 variant, rs778294 (M19). For the AA 
genotype, 50 % of probands progressed to psychosis (5 out of 10 
probands with the AA genotype). In contrast, only 13.2% of probands 
with the GG genotype progressed. Heterozygous GA probands 
experienced a progression to psychosis in 32.4% of cases. The 
increased likelihood of progression for the AA genotype was nominally 
significant (chi2= 7.027, df=2, p=0.030).  
 A linkage plot of the nine variants analysed in the 82 prodromal probands 
is shown in figure 1. As can be seen, the analysed markers segregate 
into two haplotype blocks. Markers rs1341402 and rs778294 are located 
in the same haplotype block 1.  Given a D’ of 0.95 between markers 
rs1341402 and rs778294, we constructed a two-marker haplotype 
comprising these two variants. Haplotype analysis of this two-marker 
haplotype revealed two haplotypes which had an impact on the 
progression of prodromal patients to psychosis (table 2). Thus, haplotype 
C-A is present in 35.7% of prodromal patients who progressed to 
psychosis, but only in 17.1 % of prodromal subjects who remained stable 
(p= 0.046; Bonferroni corrected p value). Conversely, haplotype T-G is 
present in 72 % of prodromal subjects who remained stable, compared 
to 50 % of prodromal patients who progressed to psychosis (p=0.031; 
Bonferroni corrected p value). Thus, haplotype C-A increases the 
susceptibility for progression to psychosis, while haplotype T-G is 
protective. The global p value for this haploype analysis was p=0.047. 
 
When haplotype analysis was performed on all six markers contained in 
haplotype block 1, no significant association of the six-marker haplotypes 
with progression to psychosis was seen (p=0.21; likelihood ratio test). 
Similarly, haplotype analysis of the markers in block 2 was not significant 
(p=0.295; likelihood ratio test). 
 
Next, we assessed whether the Positive And Negative Syndrome Scale 
(PANSS) scores at study entry were related to the long term progression 
of the disorder. PANSS scores at study entry were available for 75 out of 
the 82 study probands. Positive symptom scores at study entry related 
with later progression: those probands who would progress during the 
study period had an initial score of 13.53, compared to 10.64 for those 
probands who remained stable (F=9.030; p=0.004). Negative symptoms 
and total PANSS scores also showed an, albeit lesser, influence. Thus, 
probands with later progression had an initial negative symptom score of 
15.0, compared to those who remained stable (12.34; F=5.690; p=0.02). 
For total PANSS scores, the respective values were 60.37 (later 
progression) and 52.04 (stable probands; F=6.196; p=0.015). Global 
PANSS scores did not relate to progression. 
 
Finally, we queried whether DAOA/G72 marker rs1341402, which had 
the greatest influence on progression, also had an influence on PANSS 
scores at study entry. We found that the probands with the CC genotype, 
all of whom later progressed to psychosis, had higher PANSS scores at 
study entry compared to the other genotypes (table 3). For example, 
probands with the CC genotype had a positive PANSS score of 16.5, 
compared to 11.08 for the TT / CT genotypes (p=0.025). A similar 
difference was found for negative symptoms: 17.25 vs. 12.77 (p=0.033). 
Moreover, similar findings were seen in the haplotype analysis (table 4). 
Thus, probands with two copies of the risk-haplotype C-A had higher 
positive symptom scores at study entry (16.50; p=0.014), and probands 
lacking the protective haplotype T-G also had higher positive (14.56; 
p=0.012) and total (63.22; p=0.03) PANSS scores at study entry, 
compared to the other haplotypes (table 4).  
 
Discussion 
 
This is one of the first prospective studies of prodromal subjects that 
assesses the contribution of genetic variants to the risk of progression to 
psychosis. In a multicenter study, we have identified probands with a 
prodromal state and followed them longitudinally to assess the 
progression of symptoms. 
 
Two variants of DAOA/G72 had an important influence on the 
progression of the prodromal subjects. Thus, all homozygous carriers of 
the C allele of rs1341402 experienced a progression of symptoms. 
Similarly, 50% of probands homozygous for the A allele of rs778294 
(M19) had a progression of symptoms. Therefore, these variants of 
DAOA/G72 identify probands at a very high risk of progression, despite 
the overall risk of progression of the probands in the prodromal state 
being much lower: in the overall sample, 21 out of 82 study subjects 
experienced a transition, corresponding to 25.6 % of prodromal subjects. 
The relative risk for progression to psychosis was significantly increased 
in homozygous carriers of the rs1341402 C allele (RR = 4.588, 95 % C.I. 
= 2.175 – 4.588, p = 0.003). The increase in relative risk for subjects 
homozygous for the rs778294 (M19) A allele failed to reach significance 
(RR = 2.250, 95 % C.I. = 0.967-3.987, p = 0.114). These results indicate 
that genetic variants in the DAOA gene may substantially potentiate the 
risk for subsequent psychosis in subjects with prodromal symptoms, and 
may thus aid in treatment decisions. 
 
Our findings raise the question of the mechanism by which DAOA/G72 
determines the increased risk for prodromal probands to develop 
schizophrenia. The DAOA/G72 gene has since its discovery been 
described as the activator of D-amino acid oxidase (DAO) [4]. Given that 
this enzyme oxidises D-serine, which is an agonist at glutamatergic 
NMDA receptors, DAOA/G72 has been linked to the glutamate 
dysfunction hypothesis of schizophrenia. Very recently, G72 has also 
been linked to a neurodevelopmental role. Thus, G72 was found to 
promote dendritic branching in hippocampal neurons by way of 
expression in the mitochondria. This effect was seen only during the 
period of active dendritogenesis in synaptically immature neurons [13]. 
Moreover, expression of G72 protein in the amygdala was confirmed 
[13]. It is currently not known which effect of the DAOA/G72 gene, 
namely the D-serine/glutamate pathway or the mitochondrial function 
pathway, is mainly responsible for the role of DAOA/G72 in 
schizophrenia. Both mechanisms could contribute to the structural and 
functional brain alterations that may precede the onset of schizophrenia 
[16, 18, 21]. 
 
A meta-analysis of published association studies found highly significant 
associations between variants of DAOA/G72 and schizophrenia as well 
as less significant evidence of an association with bipolar disorder [5], 
although a very recent meta-analysis showed weaker effects [20]. The 
associated markers varied across studies. Thus, it remained unclear 
whether the associated markers all reflect the same functional variation 
or, more likely, multiple functionally important variants are present in a 
large region encompassing DAOA/G72 [5]. Notably, markers rs778293 
(M22), rs3913842 (M23), and rs1421292 (M24) which we have 
previously shown to be associated with schizophrenia [19] show no 
linkage disequilibrium with the other markers analysed. This further 
suggests that there is more than one functional allele contributing to 
schizophrenia susceptibility in the DAOA/G72 region. Interestingly, these 
three markers are located more than 50 kb downstream of the coding 
region of DAOA/G72. The only other gene in this area is a hypothetical 
gene called G30, which is located on the opposite strand and might 
provide antisense regulation of the DAOA/G72 transcript. These three 
markers are therefore likely to exert effects independent from the other 
DAOA/G72 markers. In our study, these three markers did not influence 
progression of prodromal probands, in contrast to the markers located in 
the putative promotor region or in the coding region of DAOA/G72.  
 
We then queried whether the variants relating to symptom progression of 
prodromal patients may be functional. The variant most strongly 
associated with progression of prodromal subjects is rs1341402. This 
variant is located at position –2854 with respect to the transcription start 
site. It is thus located in the extended putative promotor region of G72. 
Since common promotor variants frequently have major influence on the 
expression level of the gene product, rs1341402 is an excellent 
functional candidate variant in the promotor region of G72. The second 
variant relating to symptom progression is rs778294 (M19). This variant 
is situated 15 bp upstream of the 5´ end of a protein-coding exon of G72 
[4]. As Chumakov et al. note, this variant is part of the consensus 
sequence of an acceptor splice site and thus could potentially alter the 
splicing of G72 [4]. This variant is in high linkage disequilibrium with the 
mostly associated variant rs1341402, with a D´ value of 0.95 (figure 1). A 
variant which does not relate to symptom progression of prodromal 
subjects is rs2391191 (M15). This is a coding variant of G72, leading to a 
lysine/arginine exchange. Since this is a conservative amino acid 
exchange, it is not surprising that this variant does not relate to symptom 
progression in prodromal subjects. 
 
Progression of prodromal probands to schizophrenia has previously 
been investigated with regard to the neuregulin 1 (NRG1) gene. An 
NRG1 variant was related to progression to schizophrenia in prodromal 
probands [9]. The same variant was implicated in the developement of 
psychosis in high-risk subjects for psychosis [7]. The sample size of the 
study group in these two studies was similar to the present study, with 67 
prodromal probands [9] and 79 high-risk subjects [7] investigated 
respectively, compared to 82 prodromal probands in the present study.  
 
In conclusion, DAOA/G72 is one of the first genes identified to influence 
the risk of symptom progression of schizophrenia prodromal probands. 
Variation in DAOA/G72 identified here explains part of the risk of 
progression. We anticipate that other genes, acting either alone or in 
concert with DAOA/G72 and NRG1, will be identified in the future to also 
influence the risk of progression to schizophrenia. These other genes 
may act in the same pathophysiological pathways as DAOA/G72, or 
operate in different pathogenic biochemical pathways. Thus it may be 
feasible in the future to establish a risk profile of prodromal probands 
according to their combination of risk alleles and identify those probands 
in whom a prophylactic treatment with neuroleptics or other as-yet-to-be-
discovered treatment modalities should be instituted immediately to 
prevent progression to schizophrenia. 
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Figure legends 
 
Figure 1: Haplotype block structure of the nine analysed SNPs spanning 
the DAOA/G72 gene. The variants segregate into two haplotype blocks. 
Haplotype block structure was determined in the 82 prodromal subjects 
employing the solid spine of LD method as implemented in Haploview. 
The location of DAOA/G72 is also shown. 
Table 1: Progression of prodromal probands to psychosis stratified according to DAOA/G72 genotype 
 
Polymorphism  Progression to psychosis according to genotype  Chi2  p‐value 
rs1935058  TT: 9/26 
(34.6%) 
TC: 7/38 
(18.4%) 
CC: 5/18 
(27.8%) 
2.182  0.336 
rs1341402  TT: 10/49 
(20.4%) 
TC: 7/29 
(24.1%) 
CC: 4/4 (100%)  12.348  0.002** 
rs2391191 
(M15) 
GG: 11/34 
(32.4%) 
GA: 7/36 
(19.4%) 
AA: 3/12 
(25.0%) 
1.532  0.465 
rs1935062  AA: 12/39 
(30.8%) 
AC: 6/30 
(20.0%) 
CC: 3/13 
(23.1%) 
1.084  0.582 
rs947267 
(M18) 
AA: 3/20 (15%)  AC: 10/41 
(24.4%) 
CC: 8/21 
(38.1%) 
2.932  0.231 
rs778294 
(M19) 
GG: 5/38 
(13.2%) 
GA: 11/34 
(32.4%) 
AA: 5/10 
(50.0%) 
7.027  0.030* 
rs778293 
(M22) 
AA: 7/29 
(24.1%) 
AG: 10/44 
(22.7%) 
GG: 4/9 
(44.4%) 
1.901  0.387 
rs3918342 
(M23) 
CC: 8/23 
(34.8%) 
CT: 10/39 
(25.6%) 
TT: 3/20 
(15.0%) 
2.198  0.333 
rs1421292 
(M24) 
TT: 8/24 
(33.3%) 
TA: 10/40 
(25.0%) 
AA: 3/18 
(16.7%) 
1.515  0.469 
Probands progressing to psychosis / number of prodromal probands with a given genotype are 
shown. 
Single nucleotide polymorphism nomenclature is based on NCBI dbSNP build 129 (April 2008, 
updated June 2008). 
The traditional M nomenclature as described by Chumakov et al. is also given, whenever applicable. 
Nominal p values are shown. The nominal significance level is set at p< 0.05 (the significance 
threshold is 0.01 after correction for multiple testing according to Nyholt 2004 / Li and Ji 2005). 
** df=2; Monte Carlo simulation yielded a significance of p=0.004 
* df=2; Monte Carlo simulation yielded a significance of p=0.035 
Table 2:  Haplotype analysis of the two‐marker haplotype rs1341402‐rs778294 of DAOA/G72 in 
prodromal subjects 
Haplotype 
(rs1341402‐rs778294) 
Frequency in patien
progressing to 
ts 
psychosis 
s 
 
 Frequency in proband
remaining stable
p value#
T‐G  50.0 %     72.0 % 0.031*
T‐A  14.3 %     9.93 % > 0.1
C‐A  35.7 %     17.1 % 0.046*
 
The global significance of this haplotype analysis was p=0.047 ( likelihood ratio test ) 
# p values are Bonferroni corrected 
* p value significant after Bonferroni correction 
Table 3: PANSS scores at study entry stratified according to  DAOA/G72 rs1341402 genotype 
 
PANSS scales  rs1341402 CC  rs1341402 TT/TC  p‐value* 
positive symptoms  16.5 ± 5.06  11.08 ± 3.55  0.025 
negative symptoms  17.25 ± 3.30  12.77 ± 4.27  0.033 
global PANSS score  34.75 ± 7.63  29.47 ± 7.03  0.171 
total PANSS score  68.5 ± 14.47  53.33 ± 12.58  0.047 
 
* Mann‐Whitney‐Test with two‐sided Monte‐Carlo significance. 10000 simulations with a start value 
of 2000000 were done. 
 
Table 4: PANSS scores at study entry stratified according to DAOA/G72 two marker haplotype 
rs1341402‐rs778294 
 
PANSS scales  Haplotype T‐G  P 
value 
Haplotype C‐A  P 
value 
  0 x  1 x  2 x    0 x  1 x  2 x   
positive 
symptoms 
14.56 ± 
3.81 
10.39 ± 
3.41 
11.48 ± 
3.79 
0.012  11.35 ± 
3.77 
10.60 ± 
3.12 
16.50 ± 
3.81 
0.014 
negative 
symptoms 
15.11 ± 
4.78 
12.09 ± 
4.20 
13.36 ± 
4.22 
0.148  12.67 ± 
4.19 
12.96 ± 
4.51 
17.25 ± 
3.30 
0.128 
global PANSS 
score 
33.56 ± 
5.64 
28.21 ± 
7.56 
30.27 ± 
6.71 
0.116  29.43 ± 
7.12 
29.56 ± 
7.01 
34.75 ± 
7.63 
0.357 
total PANSS 
score 
63.22 
±12.18 
50.7 ± 
12.46 
55.12 ± 
12.83 
0.030  53.46 ± 
13.14 
53.12 ± 
11.76 
68.50 ± 
14.48 
0.075 
PANSS scores are given for probands with 0, 1, or 2 copies of each haplotype. P‐values were 
calculated by one‐way ANOVA.  
 
